Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 373 active entries
Galileiweg 8
Leiden, 2333 BD
Netherlands Phone: +31 6 41890594 E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Description:
Core R&D – PLI Technologies PlatformPLI Technologies focuses on the development and integration of innovative biotechnology platforms for the controlled production of high-value biomolecules, incorporating stable isotope labelling and advanced analytical technologies. The core R&D activities are built around three strategic pillars: 1. Biological Production & Bioconversion: Development of algae- and yeast-based platforms for the sustainable production of proteins, fatty acids and other bioactive compounds from small molecules to membrane proteins.. 2. Stable Isotope Labelling: Development of technologies for the controlled ¹³C and ¹⁵N enrichment of biomass of various origin in order to produce biomolecules for applications in metabolomics, tracer studies and pharmaceutical research. 3. Advanced Analytical Technologies: Development of rapid, non-invasive IR screening methods for compositional analysis and quality control of biomass and feedstocks. Core Innovation: Integrating biotechnology, patented stable isotope labelling and advanced analytical technologies into a unified R&D platform for the controlled production, characterization and quality control of high-value biomolecules for research and industrial applications. Core PLI Advisory provides strategic and legal advisory services at the intersection of technology, law and investment. Its focus areas include contract drafting and negotiation, intellectual property protection, and technology assessments supporting investors in making informed go/no-go decisions. Where relevant, tax law expertise is also incorporated.
Selected Categories:
Last update of this entry: November 22, 2026
|